Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial

Marti, F.E. Marti; Jayson, Gordon C; Manoharan, Prakash; O’Connor, James P.B.; Renehan, Andrew G; Backen, Alison; Mistry, Hitesh; Ortega, Fernando; Li, K.; Simpson, Kathryn; Allen, Jill N.; Connell, Jacqueline; Underhill, Stuart; Misra, Vivek; Williams, Kaye J.; Stratford, Ian J.; Jackson, Alan; Saunders, Mark

doi:10.1016/j.ejca.2019.04.029

Cited by 7 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this case, the clinical combination also showed promising efficacy [42]. Further encouraging results were reported for the preclinical testing of cediranib plus radiotherapy in CRC xenograft models and these findings are in line with the phase I clinical trial combining cediranib plus chemo-radiotherapy [24,43].…”

Section: Tkis In Combination Therapiessupporting

confidence: 75%

Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer

Iyer¹,

Erp²,

Tauriello³

et al. 2022

Cancer Treatment Reviews

View full text Add to dashboard Cite

Section: Tkis In Combination Therapiessupporting

confidence: 75%

Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer

Iyer¹,

Erp²,

Tauriello³

et al. 2022

Cancer Treatment Reviews

View full text Add to dashboard Cite

“…Amongst them, AZD1480 is an inhibitor of Janus kinases 1 and 2, and has been used in clinical trials studying the treatment of solid malignancies, post-polycythemia vera, primary myelofibrosis (PMF), and essential thrombocythemia myelofibrosis. Cediranib, an inhibitor of VEGFRs, has been used in a variety of clinical trials in cancer treatment such as rectal, 34 ovarian, 35 prostate, 36 and others. However, no trial has been found for treating bladder urothelial cancer.…”

Section: Discussionmentioning

confidence: 99%

Systematic analysis reveals distinct roles of USF family proteins in various cancer types

Liu,

Wang,

Meng

et al. 2023

Int J Biol Markers

View full text Add to dashboard Cite

Background Upstream stimulatory factors ( USFs) are members of the basic helix-loop-helix leucine zipper transcription factor family, including USF1, USF2, and USF3. The first two members have been well studied compared to the third member, USF3, which has received scarce attention in cancer research to date. Despite a recently reported association of its alteration with thyroid carcinoma, its expression has not been previously analyzed. Methods We comprehensively analyzed differential levels of USFs expression, genomic alteration, DNA methylation, and their prognostic value across different cancer types and the possible correlation with tumor-infiltrating immune cells and drug response by using different bioinformatics tools. Results Our findings established that USFs play an important role in cancers related to the urinary system and justify the necessity for further investigation. We implemented and offer a useful ShinyApp to facilitate researchers’ efforts to inquire about any other gene of interest and to perform the analysis of drug response in a user-friendly fashion at http://zzdlab.com:3838/Drugdiscovery/ .

show abstract

“…In addition, Dipetrillo, Pricolo (147) found that the combination of bevacizumab during TNT not only did not improve the pCR rate (20%) but also produced very high toxicity, with grade 3/4 toxicity, mainly gastrointestinal and hematological, in 19 of 25 patients (76%), which led to the early termination of the trial; the same was found in 2 other studies (127,128). This may be due to the use of OX-containing chemotherapy regimens, but even with the less intense neoadjuvant regimen (45 Gy/25F + capecitabine 825 mg/m2 bid + bevacizumab 5 (130). The NOMINATE trial is exploring the impact of adding bevacizumab to TNT therapy, but the results have not yet been reported, so we look forward to their results (149).…”

Section: Combination With Targeted Agentsmentioning

confidence: 93%

Radiotherapy in the preoperative neoadjuvant treatment of locally advanced rectal cancer

Yu,

Hao,

Huang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Radiotherapy and chemotherapy are effective treatments for patients with locally advanced rectal cancer (LARC) and can significantly improve the likelihood of R0 resection. Radiotherapy can be used as a local treatment to reduce the size of the tumor, improve the success rate of surgery and reduce the residual cancer cells after surgery. Early chemotherapy can also downgrade the tumor and eliminate micrometastases throughout the body, reducing the risk of recurrence and metastasis. The advent of neoadjuvant concurrent radiotherapy (nCRT) and total neoadjuvant treatment (TNT) has brought substantial clinical benefits to patients with LARC. Even so, given increasing demand for organ preservation and quality of life and the disease becoming increasingly younger in its incidence profile, there is a need to further explore new neoadjuvant treatment options to further improve tumor remission rates and provide other opportunities for patients to choose watch-and-wait (W&W) strategies that avoid surgery. Targeted drugs and immunologic agents (ICIs) have shown good efficacy in patients with advanced rectal cancer but have not been commonly used in neoadjuvant therapy for patients with LARC. In this paper, we review several aspects of neoadjuvant therapy, including radiation therapy and chemotherapy drugs, immune drugs and targeted drugs used in combination with neoadjuvant therapy, with the aim of providing direction and thoughtful perspectives for LARC clinical treatment and research trials.

show abstract

Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial

Cited by 7 publications

References 29 publications

Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer

Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer

Systematic analysis reveals distinct roles of USF family proteins in various cancer types

Radiotherapy in the preoperative neoadjuvant treatment of locally advanced rectal cancer

Contact Info

Product

Resources

About